Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer
- 11 August 2005
- journal article
- Published by Wiley in BJU International
- Vol. 96 (4) , 503-507
- https://doi.org/10.1111/j.1464-410x.2005.05674.x
Abstract
To characterize the clinical outcomes of androgen deprivation therapy (ADT) as the sole therapy for localized prostate cancer, and to determine independent predictors of disease progression, as recent studies indicate an increasing use of ADT. The records of all patients with cT1-4NXM0 adenocarcinoma of the prostate treated with ADT as the primary initial therapy at the Portland Veterans Affairs Medical Center between 1993 and 2000 were reviewed. Age, race, Charlson Health Index, family history, prostate-specific antigen (PSA) level, PSA density, digital rectal examination (DRE) findings, Gleason score, and percentage of positive biopsy cores at diagnosis were recorded for 81 patients. Patients had a median (SD, range) age of 73 (5.6, 58-84) years, a PSA level of 14.3 (34.6, 1.4-252) ng/mL and tumours were classified as Gleason score < or = 5 in 9% of patients, 6 in 31%, 7 in 31% and 8-10 in 30%. Outcomes extracted were PSA progression, PSA nadir, bone fractures, local progression, distant progression and overall survival. With a median (range) follow-up of 54 (6-115) months, the incidence of local progression, distant progression, bone fractures, PSA progression, and death were 10%, 7%, 25%, 21% and 41% respectively. The percentage of positive biopsy cores > or = 83%, age < 70 years, Gleason score > or = 7, abnormal DRE, and PSA nadir > or = 0.2 ng/mL were significantly associated with PSA progression by univariate analysis. The multivariate analysis identified age < 70 years (hazard ratio 6.52, 95% confidence interval 2.29-18.55) and Gleason score > or = 6 (4.0, 2.0-12.0) as independent risk factors for PSA progression. ADT resulted in modest control of localized prostate cancer, but younger patients and those with Gleason > or = 6 cancers were at higher risk of treatment failure. Toxicity, principally in the form of bone fractures, was high.Keywords
This publication has 30 references indexed in Scilit:
- The association between patient age and prostate cancer stage and grade at diagnosisBJU International, 2004
- Fracture Risk Following Bilateral OrchiectomyJournal of Urology, 2003
- Diagnosis and management of treatment-related osteoporosis in men with prostate carcinomaCancer, 2003
- Competing Risk Analysis After Radical Prostatectomy for Clinically Nonmetastatic Prostate Adenocarcinoma According to Clinical Gleason Score and Patient AgeJournal of Urology, 2002
- Feasibility Study: Watchful Waiting For Localized Low To Intermediate Grade Prostate Carcinoma With Selective Delayed Intervention Based On Prostate Specific Antigen, Histological And/Or Clinical ProgressionJournal of Urology, 2002
- EXPECTANT MANAGEMENT OF NONPALPABLE PROSTATE CANCER WITH CURATIVE INTENT:Journal of Urology, 2002
- CONSERVATIVE MANAGEMENT OF PROSTATE CANCER IN THE PROSTATE SPECIFIC ANTIGEN ERAJournal of Urology, 2001
- Treatment of Localized Prostate Cancer With Intermittent Triple Androgen Blockade: Preliminary Results in 110 Consecutive PatientsThe Oncologist, 2001
- Early Results of LH-RH Agonist Treatment with or without Chlormadinone Acetate for Hormone Therapy of Naive Localized or Locally Advanced Prostate Cancer: A Prospective and Randomized StudyJapanese Journal of Clinical Oncology, 2000
- Immediate Hormonal Therapy Compared with Observation after Radical Prostatectomy and Pelvic Lymphadenectomy in Men with Node-Positive Prostate CancerNew England Journal of Medicine, 1999